| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 223 | 2024 | 5644 | 11.500 |
Why?
|
| Graft vs Host Disease | 194 | 2024 | 3023 | 11.180 |
Why?
|
| Transplantation Conditioning | 92 | 2024 | 1593 | 6.250 |
Why?
|
| Leukemia, Myeloid, Acute | 58 | 2024 | 3606 | 4.460 |
Why?
|
| Transplantation, Homologous | 156 | 2024 | 4814 | 4.310 |
Why?
|
| Bone Marrow Transplantation | 93 | 2023 | 2696 | 3.580 |
Why?
|
| Hepatic Veno-Occlusive Disease | 22 | 2022 | 221 | 3.570 |
Why?
|
| Lymphocyte Depletion | 35 | 2022 | 602 | 3.350 |
Why?
|
| Myelodysplastic Syndromes | 31 | 2024 | 1401 | 3.310 |
Why?
|
| Hematologic Neoplasms | 63 | 2022 | 1899 | 3.100 |
Why?
|
| Polydeoxyribonucleotides | 14 | 2022 | 138 | 2.420 |
Why?
|
| Interleukin-2 | 28 | 2022 | 1890 | 2.030 |
Why?
|
| Leukemia | 28 | 2024 | 1522 | 2.030 |
Why?
|
| Lymphocyte Transfusion | 24 | 2021 | 232 | 2.010 |
Why?
|
| Cord Blood Stem Cell Transplantation | 22 | 2019 | 305 | 1.880 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 17 | 2016 | 265 | 1.830 |
Why?
|
| Tacrolimus | 22 | 2023 | 730 | 1.710 |
Why?
|
| Antilymphocyte Serum | 7 | 2018 | 482 | 1.500 |
Why?
|
| T-Lymphocytes | 48 | 2022 | 10183 | 1.440 |
Why?
|
| Recurrence | 66 | 2023 | 8487 | 1.370 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 28 | 2013 | 685 | 1.350 |
Why?
|
| Immunosuppressive Agents | 29 | 2021 | 4168 | 1.220 |
Why?
|
| Lymphoma, Non-Hodgkin | 20 | 2021 | 1378 | 1.130 |
Why?
|
| Graft vs Leukemia Effect | 13 | 2024 | 121 | 1.120 |
Why?
|
| Myeloablative Agonists | 16 | 2021 | 209 | 1.080 |
Why?
|
| Cyclophosphamide | 28 | 2023 | 2220 | 1.080 |
Why?
|
| Stem Cell Transplantation | 24 | 2023 | 1601 | 1.070 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 6 | 2024 | 496 | 1.030 |
Why?
|
| T-Lymphocytes, Regulatory | 23 | 2022 | 3076 | 1.020 |
Why?
|
| Sirolimus | 16 | 2020 | 1548 | 1.010 |
Why?
|
| Killer Cells, Natural | 18 | 2024 | 2204 | 0.960 |
Why?
|
| Adult | 292 | 2024 | 219847 | 0.940 |
Why?
|
| Disease-Free Survival | 50 | 2021 | 6830 | 0.940 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 14 | 2023 | 886 | 0.920 |
Why?
|
| Middle Aged | 284 | 2024 | 220175 | 0.890 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 14 | 2022 | 900 | 0.890 |
Why?
|
| Leukemia, Myeloid | 8 | 2021 | 696 | 0.870 |
Why?
|
| Busulfan | 13 | 2021 | 258 | 0.840 |
Why?
|
| Transplantation, Autologous | 39 | 2023 | 2120 | 0.830 |
Why?
|
| Mouth Diseases | 5 | 2018 | 238 | 0.820 |
Why?
|
| Lymphoma | 13 | 2021 | 1899 | 0.810 |
Why?
|
| Humans | 442 | 2024 | 760261 | 0.810 |
Why?
|
| Whole-Body Irradiation | 17 | 2019 | 433 | 0.800 |
Why?
|
| Survival Analysis | 53 | 2018 | 10185 | 0.790 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2017 | 1539 | 0.790 |
Why?
|
| Antigens, CD | 27 | 2022 | 4002 | 0.790 |
Why?
|
| Multiple Organ Failure | 10 | 2021 | 387 | 0.790 |
Why?
|
| Antigens, CD34 | 6 | 2024 | 652 | 0.780 |
Why?
|
| Aged | 184 | 2024 | 168995 | 0.760 |
Why?
|
| Chronic Disease | 48 | 2023 | 9283 | 0.760 |
Why?
|
| Azithromycin | 1 | 2022 | 201 | 0.760 |
Why?
|
| Antibodies, Monoclonal | 30 | 2022 | 9196 | 0.740 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2023 | 11708 | 0.730 |
Why?
|
| Male | 297 | 2024 | 359413 | 0.730 |
Why?
|
| CD8-Positive T-Lymphocytes | 24 | 2024 | 4554 | 0.710 |
Why?
|
| Female | 299 | 2024 | 391011 | 0.700 |
Why?
|
| Vidarabine | 15 | 2021 | 336 | 0.700 |
Why?
|
| Cancer Vaccines | 10 | 2014 | 1044 | 0.680 |
Why?
|
| Methotrexate | 17 | 2021 | 1717 | 0.670 |
Why?
|
| Bronchiolitis Obliterans | 6 | 2022 | 212 | 0.660 |
Why?
|
| Multiple Myeloma | 19 | 2023 | 5131 | 0.650 |
Why?
|
| Hematologic Diseases | 7 | 2018 | 497 | 0.620 |
Why?
|
| Globulins | 1 | 2018 | 20 | 0.610 |
Why?
|
| HLA Antigens | 14 | 2020 | 1369 | 0.600 |
Why?
|
| Survival Rate | 43 | 2021 | 12806 | 0.580 |
Why?
|
| Interleukin-15 | 1 | 2018 | 183 | 0.580 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 13 | 2021 | 1628 | 0.580 |
Why?
|
| Tissue Donors | 25 | 2024 | 2314 | 0.570 |
Why?
|
| Acute Disease | 30 | 2020 | 7268 | 0.540 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2016 | 1811 | 0.540 |
Why?
|
| Diarrhea | 3 | 2021 | 1341 | 0.530 |
Why?
|
| Fibrinolytic Agents | 7 | 2020 | 2167 | 0.530 |
Why?
|
| CD4-Positive T-Lymphocytes | 25 | 2020 | 4355 | 0.530 |
Why?
|
| Young Adult | 78 | 2024 | 58673 | 0.530 |
Why?
|
| Niacinamide | 2 | 2016 | 414 | 0.520 |
Why?
|
| Remission Induction | 23 | 2019 | 2394 | 0.520 |
Why?
|
| Dexamethasone | 5 | 2023 | 1928 | 0.510 |
Why?
|
| Treatment Outcome | 91 | 2021 | 64947 | 0.500 |
Why?
|
| Cytomegalovirus Infections | 6 | 2023 | 831 | 0.500 |
Why?
|
| Transplantation Chimera | 13 | 2024 | 595 | 0.490 |
Why?
|
| Histocompatibility | 5 | 2012 | 316 | 0.490 |
Why?
|
| Mouth Neoplasms | 2 | 2018 | 593 | 0.480 |
Why?
|
| Phenylurea Compounds | 2 | 2016 | 529 | 0.480 |
Why?
|
| B-Lymphocytes | 19 | 2022 | 4739 | 0.470 |
Why?
|
| Antineoplastic Agents | 20 | 2023 | 13629 | 0.470 |
Why?
|
| Ultraviolet Therapy | 1 | 2014 | 84 | 0.470 |
Why?
|
| Pyrazines | 5 | 2024 | 1200 | 0.470 |
Why?
|
| Cytogenetic Analysis | 4 | 2009 | 271 | 0.460 |
Why?
|
| Retrospective Studies | 89 | 2024 | 80301 | 0.460 |
Why?
|
| Graft vs Tumor Effect | 7 | 2016 | 68 | 0.460 |
Why?
|
| Adolescent | 80 | 2024 | 87747 | 0.450 |
Why?
|
| Fetal Blood | 9 | 2018 | 1343 | 0.450 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2024 | 5640 | 0.440 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2024 | 1442 | 0.420 |
Why?
|
| Combined Modality Therapy | 25 | 2021 | 8551 | 0.420 |
Why?
|
| Histocompatibility Testing | 13 | 2016 | 717 | 0.400 |
Why?
|
| Antibodies | 6 | 2017 | 2424 | 0.400 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 652 | 0.390 |
Why?
|
| Germinal Center | 3 | 2022 | 379 | 0.390 |
Why?
|
| Hypercholesterolemia | 2 | 2011 | 1155 | 0.380 |
Why?
|
| Cytomegalovirus | 4 | 2021 | 756 | 0.380 |
Why?
|
| Bone Marrow Purging | 7 | 1998 | 108 | 0.370 |
Why?
|
| Lymphocyte Activation | 19 | 2022 | 5498 | 0.370 |
Why?
|
| Graft Survival | 20 | 2017 | 3793 | 0.370 |
Why?
|
| Thrombotic Microangiopathies | 3 | 2022 | 124 | 0.370 |
Why?
|
| Survivors | 3 | 2018 | 2367 | 0.370 |
Why?
|
| Immunologic Memory | 7 | 2024 | 1354 | 0.360 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2017 | 225 | 0.360 |
Why?
|
| Hematopoietic Stem Cells | 7 | 2017 | 3390 | 0.350 |
Why?
|
| Prognosis | 43 | 2022 | 29636 | 0.350 |
Why?
|
| Erythema | 2 | 2010 | 262 | 0.340 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 1828 | 0.340 |
Why?
|
| Cytogenetics | 2 | 2007 | 198 | 0.330 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2011 | 412 | 0.330 |
Why?
|
| Immunoglobulin G | 9 | 2023 | 4546 | 0.320 |
Why?
|
| Siblings | 2 | 2012 | 825 | 0.320 |
Why?
|
| Aniline Compounds | 2 | 2024 | 1068 | 0.320 |
Why?
|
| Quality of Life | 12 | 2024 | 13300 | 0.310 |
Why?
|
| B-Cell Activating Factor | 5 | 2014 | 115 | 0.310 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2016 | 628 | 0.310 |
Why?
|
| Geriatric Assessment | 3 | 2022 | 1405 | 0.310 |
Why?
|
| Hypertriglyceridemia | 1 | 2011 | 316 | 0.300 |
Why?
|
| Time Factors | 37 | 2021 | 40133 | 0.290 |
Why?
|
| Pulmonary Edema | 1 | 2010 | 409 | 0.290 |
Why?
|
| Drug Interactions | 2 | 2011 | 1426 | 0.290 |
Why?
|
| Antibodies, Neoplasm | 6 | 2010 | 280 | 0.290 |
Why?
|
| Lymphocytes | 7 | 2014 | 2612 | 0.290 |
Why?
|
| Follow-Up Studies | 37 | 2021 | 39254 | 0.290 |
Why?
|
| Pyrimidines | 6 | 2015 | 3011 | 0.290 |
Why?
|
| Mutation | 17 | 2024 | 29950 | 0.280 |
Why?
|
| Lymphocyte Count | 7 | 2019 | 780 | 0.280 |
Why?
|
| Myeloproliferative Disorders | 4 | 2022 | 612 | 0.280 |
Why?
|
| Fever | 3 | 2016 | 1618 | 0.280 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 626 | 0.280 |
Why?
|
| Antigens, Surface | 5 | 2017 | 1616 | 0.280 |
Why?
|
| Steroids | 9 | 2023 | 928 | 0.270 |
Why?
|
| Opportunistic Infections | 2 | 2023 | 377 | 0.270 |
Why?
|
| Incidence | 28 | 2023 | 21378 | 0.270 |
Why?
|
| Immunologic Factors | 2 | 2014 | 1589 | 0.270 |
Why?
|
| Endpoint Determination | 1 | 2009 | 597 | 0.270 |
Why?
|
| Piperazines | 5 | 2016 | 2520 | 0.270 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2020 | 1870 | 0.270 |
Why?
|
| Iron Overload | 4 | 2012 | 240 | 0.260 |
Why?
|
| Immunotherapy | 6 | 2019 | 4637 | 0.260 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2024 | 645 | 0.260 |
Why?
|
| Prospective Studies | 31 | 2022 | 54263 | 0.260 |
Why?
|
| Minor Histocompatibility Antigens | 5 | 2011 | 293 | 0.260 |
Why?
|
| Mediastinal Neoplasms | 2 | 2019 | 402 | 0.260 |
Why?
|
| Melphalan | 7 | 2019 | 421 | 0.260 |
Why?
|
| Lymphoma, Follicular | 6 | 2011 | 453 | 0.250 |
Why?
|
| Lymphoma, B-Cell | 5 | 2019 | 935 | 0.250 |
Why?
|
| Lipoprotein-X | 1 | 2005 | 5 | 0.250 |
Why?
|
| Double-Blind Method | 6 | 2021 | 12412 | 0.250 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2018 | 619 | 0.250 |
Why?
|
| Melanoma | 12 | 2010 | 5695 | 0.250 |
Why?
|
| Hematology | 1 | 2009 | 241 | 0.250 |
Why?
|
| Adoptive Transfer | 3 | 2016 | 825 | 0.250 |
Why?
|
| Age Factors | 14 | 2024 | 18415 | 0.240 |
Why?
|
| Receptors, Interleukin-2 | 6 | 2006 | 562 | 0.240 |
Why?
|
| Azacitidine | 2 | 2024 | 334 | 0.240 |
Why?
|
| Dioxygenases | 3 | 2021 | 343 | 0.230 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 3201 | 0.230 |
Why?
|
| Acute Kidney Injury | 4 | 2023 | 1935 | 0.230 |
Why?
|
| Research Personnel | 1 | 2009 | 584 | 0.230 |
Why?
|
| Bone Marrow | 10 | 2022 | 2918 | 0.230 |
Why?
|
| Graft Rejection | 5 | 2024 | 4423 | 0.220 |
Why?
|
| Drug Resistance | 4 | 2019 | 1617 | 0.220 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2019 | 975 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 6 | 2013 | 693 | 0.220 |
Why?
|
| Mouth Mucosa | 3 | 2014 | 426 | 0.220 |
Why?
|
| Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
| Diet | 1 | 2021 | 8008 | 0.210 |
Why?
|
| Clinical Trials as Topic | 7 | 2012 | 8058 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2023 | 1401 | 0.210 |
Why?
|
| Hodgkin Disease | 4 | 2017 | 1381 | 0.210 |
Why?
|
| Immunophenotyping | 11 | 2016 | 1870 | 0.210 |
Why?
|
| Stomatitis | 3 | 2016 | 271 | 0.210 |
Why?
|
| Career Choice | 1 | 2009 | 755 | 0.200 |
Why?
|
| Cohort Studies | 26 | 2018 | 41317 | 0.200 |
Why?
|
| Receptors, Complement 3b | 2 | 2021 | 135 | 0.200 |
Why?
|
| Neoplasm, Residual | 5 | 2024 | 1008 | 0.200 |
Why?
|
| Vaccination | 4 | 2023 | 3360 | 0.200 |
Why?
|
| Severity of Illness Index | 9 | 2020 | 15827 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2023 | 9274 | 0.200 |
Why?
|
| Genomics | 1 | 2018 | 5790 | 0.200 |
Why?
|
| Leukemia, Experimental | 2 | 2020 | 225 | 0.200 |
Why?
|
| Isoantibodies | 5 | 2011 | 661 | 0.200 |
Why?
|
| HLA-C Antigens | 2 | 2016 | 147 | 0.200 |
Why?
|
| Clone Cells | 7 | 2017 | 1663 | 0.200 |
Why?
|
| Cell Separation | 5 | 2016 | 1720 | 0.200 |
Why?
|
| Recombinant Proteins | 14 | 2013 | 6543 | 0.200 |
Why?
|
| Cytarabine | 5 | 2008 | 696 | 0.190 |
Why?
|
| Forkhead Transcription Factors | 6 | 2018 | 1613 | 0.190 |
Why?
|
| BK Virus | 2 | 2020 | 124 | 0.190 |
Why?
|
| Treatment Failure | 3 | 2024 | 2646 | 0.190 |
Why?
|
| Hematopoiesis | 8 | 2020 | 2063 | 0.190 |
Why?
|
| Teaching | 1 | 2009 | 1167 | 0.190 |
Why?
|
| Neoplasm Proteins | 6 | 2021 | 3613 | 0.190 |
Why?
|
| Fusion Proteins, bcr-abl | 5 | 2004 | 431 | 0.180 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 4 | 2016 | 305 | 0.180 |
Why?
|
| Tandem Repeat Sequences | 2 | 2024 | 181 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2021 | 6545 | 0.180 |
Why?
|
| Boronic Acids | 3 | 2014 | 914 | 0.180 |
Why?
|
| Antibodies, Viral | 4 | 2023 | 3145 | 0.180 |
Why?
|
| Glucans | 1 | 2020 | 68 | 0.170 |
Why?
|
| Lymphocyte Subsets | 3 | 2001 | 310 | 0.170 |
Why?
|
| Limbic Encephalitis | 2 | 2012 | 36 | 0.170 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 266 | 0.170 |
Why?
|
| Herpesvirus 6, Human | 2 | 2012 | 96 | 0.170 |
Why?
|
| Prednisone | 11 | 2018 | 1566 | 0.170 |
Why?
|
| Antigens, Neoplasm | 6 | 2010 | 1999 | 0.170 |
Why?
|
| Proteins | 4 | 2022 | 6030 | 0.160 |
Why?
|
| DNA, Mitochondrial | 1 | 2024 | 857 | 0.160 |
Why?
|
| beta-Glucans | 1 | 2020 | 121 | 0.160 |
Why?
|
| Viremia | 2 | 2014 | 708 | 0.160 |
Why?
|
| Transplantation, Isogeneic | 3 | 2012 | 248 | 0.160 |
Why?
|
| Child, Preschool | 15 | 2021 | 42034 | 0.160 |
Why?
|
| Receptors, CXCR5 | 2 | 2016 | 88 | 0.160 |
Why?
|
| Idiopathic Interstitial Pneumonias | 2 | 2021 | 24 | 0.160 |
Why?
|
| Neoplasms | 17 | 2022 | 22066 | 0.160 |
Why?
|
| Gene Deletion | 3 | 2019 | 2668 | 0.160 |
Why?
|
| Blood Donors | 5 | 2013 | 343 | 0.160 |
Why?
|
| Photopheresis | 1 | 2019 | 35 | 0.160 |
Why?
|
| Child | 22 | 2023 | 79758 | 0.160 |
Why?
|
| Recovery of Function | 3 | 2019 | 2982 | 0.160 |
Why?
|
| Patient Selection | 4 | 2020 | 4276 | 0.160 |
Why?
|
| Long QT Syndrome | 1 | 2023 | 465 | 0.160 |
Why?
|
| Risk Factors | 28 | 2021 | 74269 | 0.160 |
Why?
|
| Ferritins | 4 | 2012 | 598 | 0.160 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 788 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2018 | 191 | 0.150 |
Why?
|
| Aminoglycosides | 2 | 2012 | 163 | 0.150 |
Why?
|
| Flow Cytometry | 11 | 2015 | 5873 | 0.150 |
Why?
|
| Costs and Cost Analysis | 4 | 2016 | 1679 | 0.150 |
Why?
|
| Glucocorticoids | 3 | 2018 | 2143 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2011 | 533 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 436 | 0.140 |
Why?
|
| Life Tables | 8 | 2003 | 365 | 0.140 |
Why?
|
| Disease Management | 3 | 2020 | 2508 | 0.140 |
Why?
|
| Blood Component Removal | 2 | 2011 | 132 | 0.140 |
Why?
|
| Dendritic Cells | 6 | 2023 | 2730 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 608 | 0.140 |
Why?
|
| Skin Diseases | 4 | 2020 | 1089 | 0.140 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2018 | 169 | 0.140 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2017 | 26 | 0.140 |
Why?
|
| HLA-DR7 Antigen | 1 | 1996 | 28 | 0.140 |
Why?
|
| Sulfonamides | 2 | 2024 | 1973 | 0.140 |
Why?
|
| Levonorgestrel | 1 | 2017 | 74 | 0.140 |
Why?
|
| Medical Oncology | 1 | 2009 | 2321 | 0.140 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2002 | 1351 | 0.140 |
Why?
|
| Atovaquone | 1 | 2016 | 56 | 0.140 |
Why?
|
| Vasculitis | 1 | 2021 | 523 | 0.140 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2016 | 10 | 0.140 |
Why?
|
| Leukocyte Count | 4 | 2014 | 1600 | 0.140 |
Why?
|
| Mycoses | 3 | 2011 | 387 | 0.130 |
Why?
|
| Intestinal Diseases | 2 | 2012 | 507 | 0.130 |
Why?
|
| Hand Strength | 1 | 2019 | 452 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3333 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2005 | 1301 | 0.130 |
Why?
|
| Mouth | 2 | 2009 | 380 | 0.130 |
Why?
|
| Gangliosides | 1 | 1996 | 132 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2016 | 10829 | 0.130 |
Why?
|
| Cell Count | 3 | 2016 | 1838 | 0.130 |
Why?
|
| Arabinonucleosides | 1 | 2015 | 34 | 0.130 |
Why?
|
| ABO Blood-Group System | 2 | 1997 | 369 | 0.130 |
Why?
|
| Endothelial Cells | 3 | 2021 | 3537 | 0.130 |
Why?
|
| Adenine Nucleotides | 1 | 2015 | 111 | 0.130 |
Why?
|
| Risk | 11 | 2011 | 9629 | 0.130 |
Why?
|
| Multivariate Analysis | 10 | 2016 | 12156 | 0.130 |
Why?
|
| Blood Specimen Collection | 1 | 2016 | 238 | 0.130 |
Why?
|
| Aged, 80 and over | 17 | 2022 | 58947 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 185 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2018 | 3735 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 3 | 2017 | 1060 | 0.120 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2018 | 95 | 0.120 |
Why?
|
| Piperidines | 2 | 2021 | 1650 | 0.120 |
Why?
|
| Food Supply | 1 | 2021 | 542 | 0.120 |
Why?
|
| Lung Diseases | 3 | 2019 | 1915 | 0.120 |
Why?
|
| Animals | 28 | 2024 | 167940 | 0.120 |
Why?
|
| Cytokines | 7 | 2021 | 7345 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 896 | 0.120 |
Why?
|
| H-Y Antigen | 2 | 2004 | 42 | 0.120 |
Why?
|
| Interleukins | 3 | 2014 | 782 | 0.120 |
Why?
|
| Rhizomucor | 1 | 2014 | 3 | 0.120 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2019 | 498 | 0.120 |
Why?
|
| Endothelium, Vascular | 2 | 2021 | 4437 | 0.120 |
Why?
|
| Disease Progression | 12 | 2019 | 13505 | 0.120 |
Why?
|
| Liver | 5 | 2012 | 7512 | 0.110 |
Why?
|
| Immunoconjugates | 2 | 2017 | 949 | 0.110 |
Why?
|
| Antibody Formation | 6 | 2017 | 1400 | 0.110 |
Why?
|
| 16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.110 |
Why?
|
| Bradyrhizobium | 1 | 2013 | 16 | 0.110 |
Why?
|
| Colitis | 2 | 2013 | 1229 | 0.110 |
Why?
|
| Drug Therapy, Combination | 8 | 2021 | 6499 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 2 | 2010 | 1347 | 0.110 |
Why?
|
| Gait | 1 | 2019 | 812 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2013 | 1090 | 0.110 |
Why?
|
| Transplantation Immunology | 4 | 2016 | 532 | 0.110 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2013 | 49 | 0.110 |
Why?
|
| Validation Studies as Topic | 2 | 2012 | 163 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 3584 | 0.110 |
Why?
|
| Risk Assessment | 8 | 2019 | 24086 | 0.110 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2014 | 279 | 0.110 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 4900 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 734 | 0.110 |
Why?
|
| Immune Tolerance | 3 | 2019 | 2299 | 0.110 |
Why?
|
| Syndrome | 4 | 2018 | 3278 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2023 | 4024 | 0.100 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1992 | 57 | 0.100 |
Why?
|
| Mucormycosis | 1 | 2014 | 103 | 0.100 |
Why?
|
| Receptors, KIR | 1 | 2013 | 113 | 0.100 |
Why?
|
| Patient Readmission | 3 | 2016 | 3327 | 0.100 |
Why?
|
| Integrin alpha4 | 1 | 2012 | 87 | 0.100 |
Why?
|
| DNA-Binding Proteins | 5 | 2021 | 9590 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1093 | 0.100 |
Why?
|
| Administration, Topical | 4 | 2020 | 697 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2013 | 247 | 0.100 |
Why?
|
| Vaccines, Attenuated | 1 | 2013 | 316 | 0.100 |
Why?
|
| Integrin beta Chains | 1 | 2012 | 115 | 0.100 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2011 | 355 | 0.100 |
Why?
|
| Infant | 8 | 2021 | 36030 | 0.100 |
Why?
|
| Mice | 20 | 2024 | 81216 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2018 | 3605 | 0.100 |
Why?
|
| Immunocompromised Host | 3 | 2014 | 857 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2011 | 383 | 0.100 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 2623 | 0.100 |
Why?
|
| Chelation Therapy | 1 | 2012 | 77 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 877 | 0.100 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2012 | 74 | 0.100 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1745 | 0.100 |
Why?
|
| Immunity, Humoral | 3 | 2010 | 604 | 0.100 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 49 | 0.100 |
Why?
|
| Skin Neoplasms | 4 | 2023 | 5797 | 0.100 |
Why?
|
| Oral Health | 1 | 2017 | 484 | 0.100 |
Why?
|
| Topography, Medical | 1 | 2011 | 37 | 0.100 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 195 | 0.100 |
Why?
|
| Homeostasis | 3 | 2013 | 3305 | 0.100 |
Why?
|
| Gene Library | 6 | 2014 | 1060 | 0.100 |
Why?
|
| Ovarian Neoplasms | 3 | 2024 | 4875 | 0.100 |
Why?
|
| Benzamides | 4 | 2005 | 1369 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2014 | 584 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 3618 | 0.090 |
Why?
|
| Iron Chelating Agents | 1 | 2012 | 138 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2022 | 2702 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 1993 | 333 | 0.090 |
Why?
|
| Gene Expression | 6 | 2016 | 7592 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2019 | 1180 | 0.090 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 438 | 0.090 |
Why?
|
| Integrins | 3 | 2009 | 840 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 2003 | 0.090 |
Why?
|
| Physician Assistants | 1 | 2013 | 188 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 59 | 0.090 |
Why?
|
| STAT5 Transcription Factor | 3 | 2017 | 264 | 0.090 |
Why?
|
| Oral Ulcer | 2 | 2009 | 96 | 0.090 |
Why?
|
| Infusions, Intravenous | 5 | 2012 | 2235 | 0.090 |
Why?
|
| Academic Medical Centers | 2 | 2013 | 2753 | 0.090 |
Why?
|
| Neprilysin | 1 | 1993 | 472 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2019 | 2536 | 0.090 |
Why?
|
| Blood Coagulation Factors | 1 | 2012 | 366 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2020 | 1802 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 5 | 2020 | 6226 | 0.090 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2010 | 110 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2020 | 1723 | 0.090 |
Why?
|
| Bacteremia | 1 | 2017 | 979 | 0.090 |
Why?
|
| Sezary Syndrome | 1 | 2011 | 77 | 0.090 |
Why?
|
| Immunity, Innate | 3 | 2011 | 3046 | 0.090 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2003 | 490 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 2 | 2005 | 397 | 0.090 |
Why?
|
| Observation | 1 | 2011 | 312 | 0.090 |
Why?
|
| HLA-A2 Antigen | 3 | 2022 | 211 | 0.090 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 1067 | 0.090 |
Why?
|
| Radiation Injuries | 2 | 2011 | 1183 | 0.080 |
Why?
|
| Oral Medicine | 1 | 2009 | 31 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 309 | 0.080 |
Why?
|
| Mice, Knockout | 6 | 2024 | 14396 | 0.080 |
Why?
|
| Rectum | 1 | 2014 | 896 | 0.080 |
Why?
|
| Pyrazoles | 2 | 2023 | 1992 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2010 | 253 | 0.080 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 12532 | 0.080 |
Why?
|
| Hemolytic-Uremic Syndrome | 2 | 2005 | 106 | 0.080 |
Why?
|
| Immunomagnetic Separation | 2 | 2011 | 79 | 0.080 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2010 | 825 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2005 | 4440 | 0.080 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2011 | 124 | 0.080 |
Why?
|
| Boston | 6 | 2019 | 9282 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2020 | 4494 | 0.080 |
Why?
|
| Nuclear Proteins | 3 | 2018 | 5793 | 0.080 |
Why?
|
| Mycosis Fungoides | 1 | 2011 | 167 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 1 | 2011 | 513 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 1991 | 446 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 1995 | 1041 | 0.080 |
Why?
|
| Transplantation | 1 | 2011 | 218 | 0.080 |
Why?
|
| Job Application | 1 | 2009 | 38 | 0.080 |
Why?
|
| Chromosomes, Human, Y | 1 | 2010 | 161 | 0.080 |
Why?
|
| Length of Stay | 7 | 2015 | 6472 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 2002 | 0.080 |
Why?
|
| Neoplasm Metastasis | 5 | 2003 | 4891 | 0.080 |
Why?
|
| Skin | 2 | 2020 | 4468 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2014 | 746 | 0.080 |
Why?
|
| Peptide Fragments | 3 | 2014 | 5120 | 0.080 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2019 | 1634 | 0.080 |
Why?
|
| K562 Cells | 4 | 2013 | 640 | 0.080 |
Why?
|
| Nitriles | 1 | 2014 | 955 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2014 | 968 | 0.080 |
Why?
|
| Bronchi | 1 | 2012 | 848 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 877 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 8498 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2016 | 1056 | 0.080 |
Why?
|
| Premedication | 2 | 2008 | 253 | 0.080 |
Why?
|
| Cryopreservation | 3 | 2021 | 720 | 0.080 |
Why?
|
| Triazoles | 1 | 2014 | 904 | 0.080 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 1295 | 0.080 |
Why?
|
| Financial Support | 1 | 2009 | 116 | 0.080 |
Why?
|
| Spinal Nerves | 1 | 2008 | 91 | 0.080 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 7803 | 0.080 |
Why?
|
| Interferon-gamma | 6 | 2020 | 3160 | 0.070 |
Why?
|
| Pilot Projects | 6 | 2012 | 8553 | 0.070 |
Why?
|
| Salvage Therapy | 4 | 2006 | 1266 | 0.070 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2009 | 241 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 590 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 7400 | 0.070 |
Why?
|
| Income | 1 | 2016 | 1876 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 8 | 2020 | 22025 | 0.070 |
Why?
|
| Secondary Prevention | 3 | 2005 | 1548 | 0.070 |
Why?
|
| Bone Marrow Cells | 6 | 2013 | 2424 | 0.070 |
Why?
|
| Thymus Gland | 2 | 2010 | 1246 | 0.070 |
Why?
|
| Financing, Organized | 1 | 2009 | 204 | 0.070 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2006 | 11 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2015 | 2415 | 0.070 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2007 | 65 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2016 | 2909 | 0.070 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2008 | 207 | 0.070 |
Why?
|
| Bilirubin | 3 | 2023 | 438 | 0.070 |
Why?
|
| Genetic Engineering | 3 | 2003 | 933 | 0.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 448 | 0.070 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2008 | 251 | 0.070 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 21065 | 0.070 |
Why?
|
| Career Mobility | 1 | 2009 | 258 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2011 | 1172 | 0.070 |
Why?
|
| Epithelium | 1 | 2011 | 1605 | 0.070 |
Why?
|
| Venous Thromboembolism | 2 | 2017 | 1866 | 0.070 |
Why?
|
| Antibody Specificity | 4 | 2011 | 1061 | 0.070 |
Why?
|
| Telomerase | 1 | 2011 | 747 | 0.070 |
Why?
|
| Virus Activation | 2 | 2012 | 319 | 0.070 |
Why?
|
| HIV-1 | 2 | 2014 | 6850 | 0.070 |
Why?
|
| Infant, Newborn | 5 | 2020 | 26168 | 0.070 |
Why?
|
| Karyotyping | 4 | 2012 | 1172 | 0.070 |
Why?
|
| Mycophenolic Acid | 3 | 2014 | 343 | 0.070 |
Why?
|
| Anemia, Aplastic | 1 | 2008 | 228 | 0.070 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2006 | 105 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2009 | 1354 | 0.070 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2023 | 927 | 0.070 |
Why?
|
| Leukocytes | 1 | 2014 | 2030 | 0.060 |
Why?
|
| Chromosome Aberrations | 2 | 2009 | 1767 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 3804 | 0.060 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1797 | 0.060 |
Why?
|
| Iron | 2 | 2012 | 1786 | 0.060 |
Why?
|
| STAT Transcription Factors | 1 | 2006 | 188 | 0.060 |
Why?
|
| Interferon-alpha | 4 | 2011 | 919 | 0.060 |
Why?
|
| Pyridines | 2 | 2015 | 2877 | 0.060 |
Why?
|
| Colon | 1 | 2013 | 1788 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2018 | 2359 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2012 | 1395 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3159 | 0.060 |
Why?
|
| Blood Platelets | 2 | 2013 | 2522 | 0.060 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 14482 | 0.060 |
Why?
|
| Necrosis | 3 | 2003 | 1612 | 0.060 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2005 | 114 | 0.060 |
Why?
|
| Living Donors | 1 | 2009 | 636 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2874 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2014 | 15680 | 0.060 |
Why?
|
| Protein Array Analysis | 3 | 2012 | 401 | 0.060 |
Why?
|
| Ligands | 2 | 2024 | 3277 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2005 | 4573 | 0.060 |
Why?
|
| Thrombocytopenia | 2 | 2008 | 1174 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2007 | 881 | 0.060 |
Why?
|
| Sick Role | 1 | 2005 | 230 | 0.060 |
Why?
|
| Leukopenia | 2 | 2017 | 212 | 0.060 |
Why?
|
| Melanoma, Experimental | 2 | 2010 | 562 | 0.060 |
Why?
|
| Case-Control Studies | 9 | 2014 | 22041 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 9 | 2013 | 6067 | 0.060 |
Why?
|
| Pandemics | 2 | 2021 | 8621 | 0.060 |
Why?
|
| Health Status | 2 | 2016 | 4081 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2012 | 5201 | 0.060 |
Why?
|
| Decision Making | 2 | 2016 | 3924 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2020 | 1837 | 0.060 |
Why?
|
| Paraproteinemias | 1 | 2006 | 246 | 0.060 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2005 | 102 | 0.060 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2005 | 130 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 5 | 2017 | 4717 | 0.060 |
Why?
|
| Viral Load | 1 | 2013 | 3323 | 0.060 |
Why?
|
| Vulvar Diseases | 1 | 2003 | 62 | 0.050 |
Why?
|
| Universities | 1 | 2009 | 983 | 0.050 |
Why?
|
| Goals | 1 | 2009 | 708 | 0.050 |
Why?
|
| Diphtheria Toxin | 1 | 2004 | 252 | 0.050 |
Why?
|
| Mentors | 1 | 2009 | 662 | 0.050 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2003 | 93 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 770 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2021 | 2823 | 0.050 |
Why?
|
| Gene Duplication | 1 | 2024 | 314 | 0.050 |
Why?
|
| Vaginal Diseases | 1 | 2003 | 103 | 0.050 |
Why?
|
| Monitoring, Physiologic | 2 | 2008 | 1784 | 0.050 |
Why?
|
| Adenine | 2 | 2021 | 976 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2024 | 468 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2020 | 2627 | 0.050 |
Why?
|
| Receptors, Opioid | 1 | 2003 | 145 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2012 | 2255 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2017 | 1408 | 0.050 |
Why?
|
| Cause of Death | 2 | 2004 | 3723 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2003 | 241 | 0.050 |
Why?
|
| Kidney | 1 | 2018 | 7072 | 0.050 |
Why?
|
| Alleles | 3 | 2021 | 6900 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2008 | 2024 | 0.050 |
Why?
|
| Fetal Proteins | 1 | 2022 | 97 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2012 | 966 | 0.050 |
Why?
|
| Immunoglobulin M | 2 | 2019 | 1529 | 0.050 |
Why?
|
| Polycythemia Vera | 1 | 2003 | 159 | 0.050 |
Why?
|
| Interleukin-11 | 1 | 2002 | 59 | 0.050 |
Why?
|
| Cell Proliferation | 4 | 2019 | 10434 | 0.050 |
Why?
|
| Genetic Variation | 3 | 2019 | 6540 | 0.050 |
Why?
|
| Drug Compounding | 2 | 2018 | 245 | 0.050 |
Why?
|
| Immunization | 2 | 2005 | 1228 | 0.050 |
Why?
|
| Leukopoiesis | 1 | 2001 | 55 | 0.050 |
Why?
|
| Cholestasis | 1 | 2005 | 374 | 0.050 |
Why?
|
| Cells, Cultured | 6 | 2016 | 18968 | 0.050 |
Why?
|
| Acetamides | 1 | 2023 | 256 | 0.050 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 111 | 0.050 |
Why?
|
| Publishing | 1 | 2009 | 837 | 0.050 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 18134 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 315 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2023 | 281 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2002 | 261 | 0.050 |
Why?
|
| Data Collection | 5 | 2011 | 3317 | 0.050 |
Why?
|
| Fatigue | 1 | 2008 | 1544 | 0.050 |
Why?
|
| Aging | 2 | 2010 | 8641 | 0.050 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.050 |
Why?
|
| Mitochondria | 1 | 2014 | 3598 | 0.050 |
Why?
|
| Genotype | 4 | 2024 | 12959 | 0.050 |
Why?
|
| Forehead | 1 | 2021 | 74 | 0.050 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 9388 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2003 | 1833 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2016 | 10340 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 979 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2020 | 9712 | 0.040 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2002 | 196 | 0.040 |
Why?
|
| Vital Capacity | 2 | 2014 | 965 | 0.040 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 2852 | 0.040 |
Why?
|
| Viral Tropism | 1 | 2021 | 102 | 0.040 |
Why?
|
| Ohio | 1 | 2021 | 333 | 0.040 |
Why?
|
| Apoptosis | 4 | 2021 | 9497 | 0.040 |
Why?
|
| Diterpenes | 1 | 2021 | 171 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 2 | 2020 | 967 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 912 | 0.040 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2000 | 67 | 0.040 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2000 | 71 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 414 | 0.040 |
Why?
|
| Phenotype | 6 | 2024 | 16543 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 617 | 0.040 |
Why?
|
| Immune System | 2 | 2002 | 795 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2022 | 307 | 0.040 |
Why?
|
| Acetates | 1 | 2021 | 322 | 0.040 |
Why?
|
| Hemorrhage | 3 | 2020 | 3604 | 0.040 |
Why?
|
| Life Change Events | 1 | 2005 | 953 | 0.040 |
Why?
|
| Complementarity Determining Regions | 1 | 2000 | 149 | 0.040 |
Why?
|
| Germany | 1 | 2021 | 875 | 0.040 |
Why?
|
| Glucuronidase | 1 | 2021 | 203 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2021 | 1955 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2003 | 1084 | 0.040 |
Why?
|
| Dermatologic Agents | 1 | 2003 | 306 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2010 | 1532 | 0.040 |
Why?
|
| Vincristine | 6 | 1998 | 1038 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 4286 | 0.040 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 16905 | 0.040 |
Why?
|
| Propylene Glycol | 1 | 2018 | 30 | 0.040 |
Why?
|
| Phosphotyrosine | 2 | 2016 | 456 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2011 | 2275 | 0.040 |
Why?
|
| Receptors, Very Late Antigen | 2 | 1997 | 74 | 0.040 |
Why?
|
| Vitamin D | 1 | 2012 | 3293 | 0.040 |
Why?
|
| Phosphorylation | 4 | 2017 | 8314 | 0.040 |
Why?
|
| Growth Substances | 1 | 2001 | 768 | 0.040 |
Why?
|
| Models, Biological | 1 | 2015 | 9468 | 0.040 |
Why?
|
| Oncogenes | 1 | 2024 | 1221 | 0.040 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 11902 | 0.040 |
Why?
|
| Scleroderma, Localized | 1 | 2019 | 87 | 0.040 |
Why?
|
| Enzyme Inhibitors | 2 | 2022 | 3726 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 328 | 0.040 |
Why?
|
| Forced Expiratory Volume | 2 | 2014 | 1810 | 0.040 |
Why?
|
| Inflammation Mediators | 2 | 2011 | 1882 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2021 | 307 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2020 | 2927 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 220 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2001 | 452 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 2477 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 1075 | 0.040 |
Why?
|
| Polyradiculoneuropathy | 1 | 1997 | 65 | 0.040 |
Why?
|
| Molecular Sequence Data | 8 | 2004 | 17628 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2012 | 5073 | 0.040 |
Why?
|
| Eosinophils | 2 | 2002 | 946 | 0.040 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1997 | 142 | 0.040 |
Why?
|
| HLA-A Antigens | 2 | 2010 | 225 | 0.040 |
Why?
|
| Hemagglutinins | 1 | 1997 | 113 | 0.040 |
Why?
|
| Gravidity | 1 | 2017 | 50 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 629 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2002 | 303 | 0.040 |
Why?
|
| Ambulatory Care | 2 | 2007 | 2783 | 0.040 |
Why?
|
| HIV Infections | 2 | 2014 | 17159 | 0.040 |
Why?
|
| Massachusetts | 2 | 2021 | 8805 | 0.040 |
Why?
|
| Blood Group Incompatibility | 1 | 1997 | 135 | 0.030 |
Why?
|
| Blood Component Transfusion | 1 | 1997 | 141 | 0.030 |
Why?
|
| United States | 8 | 2021 | 72363 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2002 | 1765 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2016 | 2918 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 1997 | 115 | 0.030 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2016 | 66 | 0.030 |
Why?
|
| Respiration Disorders | 1 | 2020 | 368 | 0.030 |
Why?
|
| Progesterone | 1 | 2021 | 742 | 0.030 |
Why?
|
| Antigens, CD20 | 2 | 2014 | 201 | 0.030 |
Why?
|
| Lymphocyte Cooperation | 1 | 2016 | 113 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 11141 | 0.030 |
Why?
|
| Heparin | 2 | 2021 | 1655 | 0.030 |
Why?
|
| Reoperation | 1 | 2006 | 4292 | 0.030 |
Why?
|
| Comorbidity | 3 | 2018 | 10552 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2001 | 1684 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 582 | 0.030 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 118 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 859 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2019 | 1760 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 1998 | 664 | 0.030 |
Why?
|
| Cholesterol | 1 | 2005 | 2925 | 0.030 |
Why?
|
| Donor Selection | 1 | 2017 | 228 | 0.030 |
Why?
|
| Prevalence | 3 | 2018 | 15687 | 0.030 |
Why?
|
| Menstruation | 1 | 2017 | 307 | 0.030 |
Why?
|
| Translocation, Genetic | 2 | 2005 | 1388 | 0.030 |
Why?
|
| Lymphopoiesis | 1 | 2016 | 133 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2017 | 877 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 489 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2014 | 1894 | 0.030 |
Why?
|
| Doxorubicin | 6 | 1998 | 2207 | 0.030 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 1995 | 91 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1996 | 1085 | 0.030 |
Why?
|
| Plasma Cells | 2 | 2016 | 592 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2019 | 581 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1995 | 194 | 0.030 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2014 | 32 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 3731 | 0.030 |
Why?
|
| Quinazolines | 1 | 2021 | 1363 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2007 | 534 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 1998 | 522 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 353 | 0.030 |
Why?
|
| Transplants | 1 | 2016 | 206 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 830 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2020 | 908 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 223 | 0.030 |
Why?
|
| Platelet Count | 1 | 2017 | 777 | 0.030 |
Why?
|
| Cell Lineage | 2 | 2016 | 2525 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1791 | 0.030 |
Why?
|
| Plasma | 1 | 1997 | 584 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2020 | 2932 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2003 | 2028 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2018 | 547 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 11064 | 0.030 |
Why?
|
| Biopsy | 3 | 2013 | 6775 | 0.030 |
Why?
|
| Interleukin-12 | 2 | 1993 | 584 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2005 | 2628 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2019 | 747 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 1996 | 616 | 0.030 |
Why?
|
| Vaccines | 1 | 2022 | 833 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1994 | 100 | 0.030 |
Why?
|
| Filgrastim | 1 | 2013 | 132 | 0.030 |
Why?
|
| Exoribonucleases | 2 | 2005 | 96 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 714 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 368 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2001 | 2777 | 0.030 |
Why?
|
| Morbidity | 1 | 2019 | 1765 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 2368 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 3217 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 2473 | 0.030 |
Why?
|
| Macrophages | 2 | 2018 | 5745 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2016 | 863 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2019 | 2414 | 0.030 |
Why?
|
| Antiviral Agents | 2 | 2021 | 3061 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 4 | 2003 | 6131 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 675 | 0.030 |
Why?
|
| Bronchography | 1 | 2012 | 76 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2002 | 801 | 0.030 |
Why?
|
| Oxazines | 1 | 2015 | 341 | 0.030 |
Why?
|
| Emotions | 1 | 2005 | 2730 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1995 | 255 | 0.030 |
Why?
|
| Benzylamines | 1 | 2013 | 248 | 0.030 |
Why?
|
| Infusions, Subcutaneous | 1 | 2012 | 43 | 0.030 |
Why?
|
| Gene Rearrangement | 2 | 2002 | 1122 | 0.030 |
Why?
|
| Hepatitis B | 1 | 1998 | 701 | 0.030 |
Why?
|
| Receptors, HIV | 1 | 2013 | 159 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 1056 | 0.030 |
Why?
|
| CD40 Ligand | 1 | 2014 | 522 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 2895 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 302 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1998 | 976 | 0.030 |
Why?
|
| Neutrophils | 3 | 2016 | 3770 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2012 | 71 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2014 | 0.030 |
Why?
|
| Vaccines, Conjugate | 2 | 2005 | 328 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 1340 | 0.020 |
Why?
|
| Intestinal Mucosa | 2 | 2014 | 3023 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2001 | 1228 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 2 | 2008 | 7468 | 0.020 |
Why?
|
| Death | 1 | 2016 | 678 | 0.020 |
Why?
|
| Morpholines | 1 | 2015 | 583 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 4312 | 0.020 |
Why?
|
| Deferoxamine | 1 | 2012 | 153 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2012 | 134 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 977 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2000 | 3531 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 15766 | 0.020 |
Why?
|
| Antigen Presentation | 2 | 2010 | 1254 | 0.020 |
Why?
|
| Fusarium | 1 | 1991 | 51 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2011 | 346 | 0.020 |
Why?
|
| Chemokine CCL3 | 1 | 2011 | 84 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 1995 | 978 | 0.020 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 1996 | 364 | 0.020 |
Why?
|
| Host vs Graft Reaction | 1 | 1990 | 13 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2015 | 564 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 527 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2003 | 1544 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2011 | 4127 | 0.020 |
Why?
|
| Aftercare | 1 | 2017 | 918 | 0.020 |
Why?
|
| Anemia, Hemolytic | 1 | 1992 | 163 | 0.020 |
Why?
|
| Hypotension | 1 | 2017 | 883 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2021 | 3207 | 0.020 |
Why?
|
| Haplotypes | 1 | 2017 | 2764 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 2005 | 642 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2011 | 398 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2013 | 487 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1992 | 282 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2017 | 2608 | 0.020 |
Why?
|
| Critical Illness | 1 | 2023 | 2709 | 0.020 |
Why?
|
| Cell Division | 2 | 2006 | 4462 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2014 | 1133 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 1990 | 168 | 0.020 |
Why?
|
| Physicians | 1 | 2008 | 4590 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 1088 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 2192 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2010 | 123 | 0.020 |
Why?
|
| Endotoxemia | 1 | 2011 | 196 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2010 | 177 | 0.020 |
Why?
|
| Eosinophilia | 1 | 1995 | 560 | 0.020 |
Why?
|
| Drug Costs | 1 | 1998 | 1184 | 0.020 |
Why?
|
| Twins | 1 | 2012 | 339 | 0.020 |
Why?
|
| Internet | 2 | 2016 | 3074 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2010 | 5039 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 2569 | 0.020 |
Why?
|
| Lichenoid Eruptions | 1 | 2009 | 13 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 1991 | 524 | 0.020 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2010 | 70 | 0.020 |
Why?
|
| Anxiety | 1 | 2005 | 4532 | 0.020 |
Why?
|
| Pancytopenia | 1 | 1990 | 101 | 0.020 |
Why?
|
| Angiopoietin-2 | 1 | 2010 | 173 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2011 | 316 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2003 | 4938 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2003 | 1993 | 0.020 |
Why?
|
| Thrombomodulin | 1 | 2010 | 105 | 0.020 |
Why?
|
| Mucocele | 1 | 2009 | 51 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2016 | 789 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 130 | 0.020 |
Why?
|
| Endotoxins | 1 | 2011 | 521 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 1346 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2010 | 344 | 0.020 |
Why?
|
| Pneumococcal Infections | 2 | 2005 | 503 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2022 | 3598 | 0.020 |
Why?
|
| Immunodominant Epitopes | 1 | 2010 | 241 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2005 | 649 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 25928 | 0.020 |
Why?
|
| Mass Screening | 1 | 2005 | 5422 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2011 | 249 | 0.020 |
Why?
|
| Hepatorenal Syndrome | 1 | 2009 | 76 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2013 | 1455 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1994 | 1558 | 0.020 |
Why?
|
| Genome, Bacterial | 1 | 2013 | 770 | 0.020 |
Why?
|
| Nucleic Acids | 1 | 2011 | 188 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 4109 | 0.020 |
Why?
|
| Base Sequence | 4 | 2003 | 12447 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 15273 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2010 | 251 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 1388 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 1972 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 2009 | 2363 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 1188 | 0.020 |
Why?
|
| Blast Crisis | 1 | 2008 | 101 | 0.020 |
Why?
|
| Calcineurin | 1 | 2008 | 229 | 0.020 |
Why?
|
| Macrocyclic Compounds | 1 | 2007 | 67 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 1897 | 0.020 |
Why?
|
| E-Selectin | 1 | 2010 | 576 | 0.020 |
Why?
|
| Antibodies, Bacterial | 2 | 2005 | 1470 | 0.020 |
Why?
|
| Amnesia, Anterograde | 1 | 2007 | 20 | 0.020 |
Why?
|
| Placebos | 2 | 2002 | 1672 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2014 | 2195 | 0.020 |
Why?
|
| Erythroblasts | 1 | 2007 | 143 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2016 | 2415 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1989 | 416 | 0.020 |
Why?
|
| Thalidomide | 1 | 2012 | 884 | 0.020 |
Why?
|
| Epitopes | 2 | 2004 | 2506 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 591 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 2001 | 375 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2003 | 5248 | 0.020 |
Why?
|
| Philadelphia Chromosome | 1 | 2007 | 117 | 0.020 |
Why?
|
| Diabetes Insipidus | 1 | 2007 | 144 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2016 | 3683 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 2004 | 13456 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 4547 | 0.020 |
Why?
|
| Drinking | 1 | 2008 | 199 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2012 | 1156 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 2249 | 0.020 |
Why?
|
| Sex Factors | 2 | 2011 | 10530 | 0.020 |
Why?
|
| Neutropenia | 1 | 2011 | 884 | 0.020 |
Why?
|
| Hepatitis C | 1 | 1996 | 1578 | 0.020 |
Why?
|
| Sacrum | 1 | 2008 | 281 | 0.020 |
Why?
|
| Self Report | 1 | 2018 | 3707 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 5796 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 1128 | 0.020 |
Why?
|
| Heterozygote | 1 | 2013 | 2797 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2005 | 38 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1856 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2014 | 2837 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2010 | 673 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 943 | 0.020 |
Why?
|
| Carboplatin | 2 | 2002 | 789 | 0.020 |
Why?
|
| Canada | 1 | 2011 | 2128 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 2775 | 0.020 |
Why?
|
| Professional Staff Committees | 1 | 2005 | 38 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 787 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 2978 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2006 | 297 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 2698 | 0.020 |
Why?
|
| RNA, Neoplasm | 2 | 2003 | 749 | 0.020 |
Why?
|
| Quality of Health Care | 2 | 2013 | 4361 | 0.020 |
Why?
|
| Lymphocytosis | 2 | 2000 | 119 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 5507 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 3604 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 15740 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2005 | 159 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2009 | 600 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2007 | 11480 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2010 | 752 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2021 | 4896 | 0.020 |
Why?
|
| Depression | 1 | 2005 | 8033 | 0.020 |
Why?
|
| RNA-Binding Proteins | 2 | 2005 | 1892 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2010 | 821 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2007 | 383 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2005 | 2945 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2005 | 346 | 0.010 |
Why?
|
| Plasma Exchange | 1 | 2005 | 158 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2805 | 0.010 |
Why?
|
| Signal Transduction | 3 | 2013 | 23363 | 0.010 |
Why?
|
| Self-Assessment | 1 | 2006 | 393 | 0.010 |
Why?
|
| Albumins | 1 | 2007 | 577 | 0.010 |
Why?
|
| Lung Neoplasms | 3 | 2005 | 13249 | 0.010 |
Why?
|
| Smoking | 1 | 2001 | 9070 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1990 | 1434 | 0.010 |
Why?
|
| Health | 1 | 2006 | 395 | 0.010 |
Why?
|
| Rabbits | 1 | 2010 | 4773 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6242 | 0.010 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2007 | 387 | 0.010 |
Why?
|
| Observer Variation | 1 | 2009 | 2596 | 0.010 |
Why?
|
| Anti-Retroviral Agents | 1 | 2013 | 1780 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 928 | 0.010 |
Why?
|
| Intestines | 1 | 2012 | 1907 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 4357 | 0.010 |
Why?
|
| Gene Fusion | 1 | 2005 | 354 | 0.010 |
Why?
|
| U937 Cells | 1 | 2003 | 262 | 0.010 |
Why?
|
| Logistic Models | 2 | 2001 | 13311 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 2002 | 155 | 0.010 |
Why?
|
| Registries | 1 | 2019 | 8449 | 0.010 |
Why?
|
| Pain | 2 | 2009 | 5066 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2003 | 197 | 0.010 |
Why?
|
| Methods | 1 | 2002 | 1075 | 0.010 |
Why?
|
| Hospitalization | 1 | 2022 | 10761 | 0.010 |
Why?
|
| Interferons | 1 | 2005 | 705 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2010 | 2119 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 2002 | 165 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 640 | 0.010 |
Why?
|
| Tyrosine | 2 | 1997 | 1440 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2002 | 246 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 20048 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2002 | 286 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 2526 | 0.010 |
Why?
|
| Marriage | 1 | 2003 | 351 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3774 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2009 | 4044 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 778 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 298 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2008 | 2434 | 0.010 |
Why?
|
| Fibrosis | 1 | 2008 | 2042 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 1746 | 0.010 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2000 | 87 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 1395 | 0.010 |
Why?
|
| Ascites | 1 | 2002 | 338 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 2641 | 0.010 |
Why?
|
| Body Fluids | 1 | 2002 | 319 | 0.010 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2000 | 121 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 6181 | 0.010 |
Why?
|
| Musculoskeletal Diseases | 1 | 2006 | 594 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 1799 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2013 | 3737 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 3483 | 0.010 |
Why?
|
| Amygdala | 1 | 2007 | 1350 | 0.010 |
Why?
|
| Myocardium | 1 | 2012 | 4688 | 0.010 |
Why?
|
| Chromosome Mapping | 2 | 2001 | 4625 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2000 | 419 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 2755 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 36247 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1990 | 2250 | 0.010 |
Why?
|
| Pneumonia, Viral | 1 | 1996 | 3206 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2003 | 539 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1998 | 108 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 1697 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2008 | 2058 | 0.010 |
Why?
|
| Pregnancy | 2 | 2017 | 29725 | 0.010 |
Why?
|
| RNA, Messenger | 3 | 2002 | 12762 | 0.010 |
Why?
|
| Testis | 1 | 2001 | 794 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3696 | 0.010 |
Why?
|
| Thalassemia | 1 | 1998 | 270 | 0.010 |
Why?
|
| Integrin alpha4beta1 | 1 | 1997 | 119 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2008 | 3514 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1997 | 103 | 0.010 |
Why?
|
| Adsorption | 1 | 1997 | 197 | 0.010 |
Why?
|
| Algorithms | 2 | 2010 | 13967 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 14656 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 4172 | 0.010 |
Why?
|
| Calcium | 1 | 1990 | 5726 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2008 | 12968 | 0.010 |
Why?
|
| Pneumonia | 1 | 2008 | 2138 | 0.010 |
Why?
|
| Estrogens | 1 | 2003 | 1520 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2002 | 1229 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 1737 | 0.010 |
Why?
|
| Genome, Human | 1 | 2009 | 4416 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 2811 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1996 | 287 | 0.010 |
Why?
|
| Consensus | 1 | 2005 | 3106 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 313 | 0.010 |
Why?
|
| DNA Probes | 1 | 1996 | 551 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2008 | 3185 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 2500 | 0.010 |
Why?
|
| Lung | 1 | 2014 | 9989 | 0.010 |
Why?
|
| Daunorubicin | 1 | 1995 | 155 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 1995 | 149 | 0.010 |
Why?
|
| Ifosfamide | 1 | 1995 | 232 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2002 | 1738 | 0.010 |
Why?
|
| Hippocampus | 1 | 2007 | 3737 | 0.010 |
Why?
|
| Ribavirin | 1 | 1996 | 396 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 2414 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 1995 | 283 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1997 | 682 | 0.010 |
Why?
|
| Etoposide | 1 | 1995 | 630 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 4358 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 3763 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2003 | 2627 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1993 | 317 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 2532 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 4920 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1998 | 1190 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 3381 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 2819 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1995 | 1158 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 1991 | 128 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1992 | 778 | 0.010 |
Why?
|
| Paraproteins | 1 | 1991 | 38 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1991 | 141 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 761 | 0.010 |
Why?
|
| Infusion Pumps | 1 | 1991 | 163 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 5396 | 0.010 |
Why?
|
| Eye Infections, Fungal | 1 | 1991 | 100 | 0.010 |
Why?
|
| Splenectomy | 1 | 1992 | 391 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1991 | 778 | 0.010 |
Why?
|
| Hematocrit | 1 | 1991 | 630 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 20484 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 1991 | 429 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 4317 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1991 | 680 | 0.000 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1990 | 245 | 0.000 |
Why?
|
| Hepatitis | 1 | 1990 | 231 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1996 | 2937 | 0.000 |
Why?
|
| Herpes Zoster | 1 | 1990 | 251 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1994 | 3096 | 0.000 |
Why?
|
| Phosphoproteins | 1 | 1996 | 2441 | 0.000 |
Why?
|
| Brain | 1 | 2014 | 26912 | 0.000 |
Why?
|
| Catheterization, Central Venous | 1 | 1991 | 526 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1990 | 507 | 0.000 |
Why?
|
| Probability | 1 | 1991 | 2476 | 0.000 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 2880 | 0.000 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1990 | 708 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 8984 | 0.000 |
Why?
|
| Lymph Nodes | 1 | 1995 | 3491 | 0.000 |
Why?
|
| Palliative Care | 1 | 1998 | 3607 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 11341 | 0.000 |
Why?
|
| Cell Line | 1 | 1991 | 15626 | 0.000 |
Why?
|